KN

Karl Nagler

Life Science Investor at Sofinnova Partners

Greater Munich Metropolitan Area

Overview 

Karl Nagler is currently a Life Science Investor at Sofinnova Partners, with a strong background in biotechnology and venture capital. He has held significant roles such as Managing Partner at Wellington Partners Life Sciences and General Partner at Ventech, showcasing his expertise in corporate development and investments within the pharmaceutical industry.

Work Experience 

SP

Sofinnova Partners

  • Partner

    2024 - Current

WP

Wellington Partners Life Sciences

  • Managing Partner

    2020 - 2024

    Representing Wellington on the boards of: - Imcheck Therapeutics (www.imchecktherapeutics.com; Marseille) - Minervax (www.minervax.com; Kopenhagen) - SIRS Therapeutics (www.wellington-partners.com/port/sirs/; Munich) - Uromems (www.uromems.com; Grenoble) - Advanced Medical Balloons (www.hyghtec.com; Waghäusel) - Confo Therapeutics (www.confotherapeutics.com; Ghent) - Seamless Therapeutics (https://seamlesstx.com; Dresden)

G

Gimv

  • Partner

    2011 - 2019

    Led Gimv's investments in, and represented Gimv on the boards of: - Precirix (www.precirix.com - Brussels) - Imcheck Therapeutics (www.imchecktherapeutics.com - Marseille) - Breath Therapeutics (Munich; acquired by Zambon) - Topas Therapeutics (www.topas-therapeutics.com - Prosonix (Oxford; acquired by Circassia, CIR:LN) and - Covagen (Zurich; acquired by Johnson & Johnson, JNJ:US); Chairman of the board Also represented Gimv on the board of Actogenix (Gent; acquired by Intrexon, XON:US)

V

Ventech

  • General Partner

    2009 - 2011

    Led Ventech's investments in, and represented Ventech on the boards of: - Prosonix (Oxford; acquired by Circassia, CIR:LN) - Covagen (Zurich; acquired by Johnson & Johnson, JNJ:US) - Funxional Therapeutics (Cambridge; acquired by Boehringer Ingelheim) - Themis (Vienna; acquired by MSD, MRK:NYS) Also represented Ventech on the board of Actogenix (Gent; acquired by Intrexon, XON:US)

AV

Atlas Venture

  • Principal

    2002 - 2009

    Led Atlas' financings in, and represented Atlas on the boards of: - Nitec Pharma (Basel; acquired by Horizon Pharma, HZNP:US) - Egalet (Kopenhagen; IPO on Nasdaq, EGLT:US) - U3 Pharma (Munich; acquired by Daiichi Sankyo, DSKYF:US)

Atlas Venture creates and invests in biotech startup companies with seed and early stage venture investments.

atlasventure.com

CNRS Centre de Neurochimie

  • Postdoctoral Research Scientist

    2001 - 2002

MD

Max Delbrueck Center

  • Research Scientist

    1999 - 2001

    PhD position: Cellular and Molecular Neurobiology

Education 

Articles About Karl

Relevant Websites